pharma · Pyruvate Kinase Deficiency · Sickle Cell Disease · AGIO
Agios Netherlands
Agios Netherlands B.V.
Agios Netherlands clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CAMBRIDGE, MA, NL
- Founded
- 1978
- Employees
- 20
- Programs
- 45
- Drugs
- 15
- Patents
- 93
Agios Netherlands projects
7 ClinicalTrials.gov programs sponsored by Agios Netherlands.
Agios Netherlands has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
AG-120
Agios Netherlands B.V.
Chondrosarcoma
1 trial -
AG-348
Agios Netherlands B.V.
Thalassemia
1 trial -
Enasidenib
Agios Netherlands B.V.
Hematologic Neoplasms
1 trial -
Mitapivat
Agios Netherlands B.V.
Anemia
1 trial -
Tebapivat
Agios Netherlands B.V.
Myelodysplastic Syndromes
1 trial -
Tebapivat
Agios Netherlands B.V.
Sickle Cell Disease
1 trial -
ivosidenib and nivolumab
Agios Netherlands B.V.
Advanced Solid Tumor
1 trial
Frequently asked questions
How many clinical projects does Agios Netherlands have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.